✦ LIBER ✦

PCV39 PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE II DIABETES A COST-MINIMIZATION ANALYSIS

✍ Scribed by P Berto; G Cremonesi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV47 DIRECT MEDICAL COSTS FOR TREATMENT

✍ P Berto; G Cremonesi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PCV79 THE COST-EFFECTIVENESS OF IRBESART

✍ S Hu; W Chen; L Annemans 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

Cost Effectiveness Analysis of a Hyperte

✍ David Ly; Fu Z. Alex; Hebert Christopher 📂 Article 📅 2009 🏛 Le Jacq Communications, Inc. 🌐 English ⚖ 240 KB

PCV32 COST-EFFECTIVENESS OF IRBESARTAN I

✍ H Hernandez; L Lepe; A Gonzalez; A Lemus 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCV72 COST-EFFECTIVENESS ANALYSIS OF ADD

✍ P Kutscherauer; R Kodym; D Bartaskova 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Cost-consequence analysis in a French se

✍ AJ Palmer; R Chen; WJ Valentine; S Roze; B Bregman; N Mehin; S Gabriel 📂 Article 📅 2006 🏛 Masson Editeur 🌐 French ⚖ 122 KB